Celecoxib Boosts Survival Odds for Colon Cancer Patients

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly extends cancer-free survival in patients, demonstrating potential as a personalized treatment approach.

New findings suggest that colon cancer patients with circulating tumor DNA (ctDNA) after surgery can enhance their survival odds by taking daily doses of the nonsteroidal anti-inflammatory drug celecoxib, popularly known as Celebrex.

Data from the American Society of Clinical Oncology Gastrointestinal Cancers Symposium shows that patients receiving celecoxib had prolonged disease-free survival compared to those on a placebo, particularly benefiting those with positive ctDNA tests.

This research marks a significant step toward personalized treatment strategies for early-stage colon cancer, offering hope for better outcomes through targeted therapy.

(With inputs from agencies.)